摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,N-bis-(tert-butoxycarbonyl)-3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine | 375853-67-1

中文名称
——
中文别名
——
英文名称
N,N-bis-(tert-butoxycarbonyl)-3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine
英文别名
tert-butyl N-[(2-methylpropan-2-yl)oxycarbonyl]-N-[[3-[1-[5-(2-phenylethynyl)pyridine-3-carbonyl]piperidin-4-yl]phenyl]methyl]carbamate
N,N-bis-(tert-butoxycarbonyl)-3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine化学式
CAS
375853-67-1
化学式
C36H41N3O5
mdl
——
分子量
595.739
InChiKey
VFWYMSSTHYUYEF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    44
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    89
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N,N-bis-(tert-butoxycarbonyl)-3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine盐酸 作用下, 以 乙酸乙酯 为溶剂, 反应 4.0h, 生成 [4-(3-aminomethyl-phenyl)-piperidin-1-yl]-(5-phenylethynyl-pyridine-3-yl)methanone dihydrochloride
    参考文献:
    名称:
    Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of βII tryptase
    摘要:
    Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase beta is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified beta-amidoester benzamidines as potent inhibitors of recombinant human betaII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.
    DOI:
    10.1016/j.bmc.2005.02.014
  • 作为产物:
    描述:
    3-溴苄溴 在 palladium on activated charcoal (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride氢气 、 sodium hydride 、 potassium carbonateN,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下, 以 四氢呋喃乙醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 25.0h, 生成 N,N-bis-(tert-butoxycarbonyl)-3-[1-(5-phenylethynyl-pyridine-3-carbonyl)-piperidin-4-yl]-benzylamine
    参考文献:
    名称:
    Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of βII tryptase
    摘要:
    Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase beta is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified beta-amidoester benzamidines as potent inhibitors of recombinant human betaII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.
    DOI:
    10.1016/j.bmc.2005.02.014
点击查看最新优质反应信息

文献信息

  • Chemical compounds
    申请人:——
    公开号:US20030187020A1
    公开(公告)日:2003-10-02
    Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.
    本文提供了具有胰蛋白酶抑制活性的新颖和有用化合物,包括含有这些化合物的药物组合物,以及治疗患有可以通过给予胰蛋白酶抑制剂(例如哮喘和炎症性疾病等)而得到改善的疾病、疾病或紊乱的方法。
  • [EN] ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS<br/>[FR] DERIVES D'ARYLMETHYLAMINE UTILISES COMME INHIBITEURS DE LA TRYPTASE
    申请人:AVENTIS PHARM PROD INC
    公开号:WO2001090101A1
    公开(公告)日:2001-11-29
    Provided herein are compounds of formula (I) wherein R1-4, n and Ar are as defined in claim 1, and their pharmaceutical compositions. These compounds are tryptase inhibitors and may be used in the treatment of e.g. asthma and inflammatory diseases.
    本发明提供了式(I)的化合物,其中R1-4、n和Ar如权利要求1所定义,以及它们的药物组成物。这些化合物是胰蛋白酶抑制剂,可用于治疗哮喘和炎症性疾病等疾病。
  • ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS
    申请人:Aventis Pharmaceuticals Inc.
    公开号:EP1296972B1
    公开(公告)日:2009-12-23
  • US6977263B2
    申请人:——
    公开号:US6977263B2
    公开(公告)日:2005-12-20
  • Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of βII tryptase
    作者:Julian Levell、Peter Astles、Paul Eastwood、Jennifer Cairns、Olivier Houille、Suzanne Aldous、Gregory Merriman、Brian Whiteley、James Pribish、Mark Czekaj、Guyan Liang、Sebastien Maignan、Jean-Pierre Guilloteau、Alain Dupuy、Jane Davidson、Trevor Harrison、Andrew Morley、Simon Watson、Garry Fenton、Clive McCarthy、Joseph Romano、Rose Mathew、Darren Engers、Michael Gardyan、Keith Sides、Jennifer Kwong、Joseph Tsay、Sam Rebello、Liduo Shen、Jie Wang、Yongyi Luo、Odessa Giardino、Heng-Keang Lim、Keith Smith、Henry Pauls
    DOI:10.1016/j.bmc.2005.02.014
    日期:2005.4
    Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase beta is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified beta-amidoester benzamidines as potent inhibitors of recombinant human betaII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.
查看更多